Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a ...

Amgen (NASDAQ:AMGN) announced on Monday that its new weight loss treatment, MariTide, resulted in an average weight loss of ...

Historic changes are afoot for pharma as China gains ground on U.S. production. The pharma industry is projected to see ...

On the Nasdaq, 2,389 stocks rose and 2,026 fell as advancing issues outnumbered decliners by a 1.18-to-1 ratio. The S&P 500 ...

Results from the Phase III REDEFINE 1 trial show that CagriSema led to a 22.7% mean weight reduction at 68 weeks in adults ...

CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

BrightGene Pharmaceutical has scored an early win in its push to topple the big beasts of the GLP-1 field. | BrightGene ...

Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments ...

GPs in England are now allowed to prescribe the weight-loss jab to some severely obese people, but many practices do not yet ...

US pharma major Eli Lilly (NYSE: LLY) spotlighted new safety and efficacy data for its investigational oral GLP-1 therapy ...

The TSX Composite Index rolled on 155.24 points to move into Monday afternoon at 26,652.81. The Canadian dollar regrouped 0.05 cents to 72.82 cents U.S. Over the weekend, the U.S. had launched strikes ...